期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Liguzinediol protects against apoptosis induced by doxorubicin in H9C2 cells
1
作者 YuLI ChaoLIN +4 位作者 ya-yunzhang YuanYAO XiangWU WeiLI Hui-minBIAN 《中国药理学与毒理学杂志》 CAS CSCD 北大核心 2015年第S1期83-83,共1页
OBJECTIVE Liguzinediol is a derivative of the natural active ingredient ligustrazine,and we found that liguzinediol has significant positive inotropic effects,which are stronger than that of TMP.Besides,it does not le... OBJECTIVE Liguzinediol is a derivative of the natural active ingredient ligustrazine,and we found that liguzinediol has significant positive inotropic effects,which are stronger than that of TMP.Besides,it does not lead to arrhythmia,hypotension and other side effects.This study aims to investigate the anti-apoptotic effects of liguzinediolon H9C2 cells.METHODS Apoptotic H9C2 cells induced by DOX were observed by electron microscope and FCM analysis.The protein expressions of Bax,Bcl-2,caspases 3 and NF-κB were detected by Western blotting.RESULTS Apoptotic H9C2 cells induced by DOX were observed,but without apoptotic bodies in liguzinediol group.Declined peak of H9C2 cell apoptosis was seen in liguzinediol group by FCM analysis.And downregulation of Bax,caspases 3,NF-κB and upregulation of Bcl-2 were found by Western blotting.CONCLUSION Liguzinediol protected cardiomyocytes against apoptosis through downregulation of Bax and caspases 3 and upregulation of Bcl-2.Liguzinediol can inhibited cardiomyocyte apoptosis through the NF-κB signal pathway. 展开更多
关键词 LIGUZINEDIOL APOPTOSIS DOXORUBICIN H9C2 cell
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部